Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Veterinary Diagnostic Labs
Transcript
- Lucas: So Luna, we've talked about private equity buying up veterinary practices, pet insurance, even pet cremation. But there's a layer underneath all of that — the diagnostic labs that run the blood work, the urinalysis, the imaging analysis. And PE has been quietly consolidating that space for the last few years. Luna: You mean the labs that vets send samples to? That's a whole different animal — pardon the pun — than buying a clinic. Lucas: Exactly. Think about it: when you take your dog to the vet for a routine checkup, they might run a chemistry panel, a complete blood count, maybe a thyroid test. Those samples get sent to a reference lab — IDEXX, Antech, or a regional player. And those labs have incredibly sticky revenue. Once a vet practice integrates with a lab's software and workflow, switching costs are high. Luna: So PE firms are buying up regional labs and trying to create a national network? Similar to the dental support organization model we covered. Lucas: Very similar. The U.S. veterinary diagnostics market is about $4.2 billion in 2026, growing at 8 percent CAGR. The two giants — IDEXX, publicly traded, and Antech, owned by Mars — control maybe 60 percent of the reference lab volume. But the remaining 40 percent is fragmented among dozens of regional labs. And that's where PE sees an opportunity. Luna: What kind of multiples are these labs trading at? Lucas: Typically 8 to 12 times EBITDA for a well-run regional lab. But the play is to buy at 8x, then roll up three or four labs, centralize processing, cut overlapping overhead, and expand the test menu. A consolidated platform might exit at 14 to 16 times EBITDA after three to five years. Luna: So the margin expansion comes from efficiency, not from raising prices on the vets? Lucas: Partly. But there's also a pricing angle. When a pe backed lab consolidates, they often renegotiate contracts with the vet practices. They might bundle tests or require minimum volumes. Some independent vets have complained that their lab costs went up 15 to 20 percent after a regional lab was acquired. Luna: And the FTC has taken notice. I recall they investigated a merger of two large lab companies a couple years ago. Lucas: Right — in 2024, the FTC challenged a proposed acquisition of a regional lab by Antech, arguing it would reduce competition in the Southwest. The deal was abandoned. But PE firms are usually more careful: they buy smaller labs in different geographies, so no single acquisition triggers antitrust review. Luna: So the strategy is to create a national footprint one small lab at a time. Who are the main pe backed players now? Lucas: The most prominent is Ethos Diagnostics — backed by a consortium led by Goldman Sachs Asset Management. They've acquired about 12 regional labs since 2022, mostly in the Midwest and Southeast. Another is VCA, which is owned by Mars but has been buying lab assets to complement its hospital network. And there's a newer entrant, Atlas Lab Partners, backed by a mid-market PE firm, focusing on the Northeast. Luna: What about the technology angle? Labs are investing in AI for reading slides, automated analyzers — does that change the acquisition thesis? Lucas: It absolutely does. A PE firm buying a regional lab that still uses manual processes can invest in automation, which drives margin. For example, a digital cytology platform can reduce the need for a pathologist on site, allowing one specialist to read slides from multiple labs. That's a direct path to higher EBITDA. Luna: So the roll-up isn't just about scale — it's about upgrading the tech stack. Lucas: Exactly. And the data is valuable too. Every test result becomes part of a database that can be used to develop predictive algorithms — for early disease detection, breed-specific risks, that kind of thing. That data asset is hard to replicate and adds to the exit multiple. Luna: But there's a tension here. Vets want fast turnaround and low prices. If PE consolidates too much, the independent vet loses leverage. Lucas: That's the concern. Some veterinary associations have voiced worries about 'lab deserts' — areas where only one lab serves a region, so the vet has no choice. We've seen that happen in human healthcare with lab consolidation, and it's a plausible risk here. Luna: Let's talk about a specific deal. I read that Ethos Diagnostics acquired Heartland Veterinary Labs in Indiana last year. What was the rationale? Lucas: Heartland was a family-owned lab doing about $25 million in revenue, serving 400 clinics across Indiana, Ohio, and Kentucky. Ethos likely paid 9 to 10 times EBITDA — say $30 to $40 million. They then moved the high-volume chemistry and hematology work to a central facility in Indianapolis, while keeping the local sample drop-off points open. Turnaround times actually improved because of automation. Luna: So the local vets saw better service, not worse. That's a smart way to do it. Lucas: It is. But the key is that Ethos also renegotiated the supplier contracts for reagents and consumables. By centralizing purchasing across their platform, they probably cut reagent costs by 15 to 20 percent. That's pure margin expansion. Luna: And the vets didn't necessarily see a price cut — they just got the same service, maybe a bit faster, while the PE firm captured the savings. Lucas: Right. That's the business model. And it works as long as the quality doesn't drop. But if a lab starts cutting corners — say, using cheaper reagents that affect accuracy — then you have a reputational problem. Veterinary diagnostics is a trust business. Luna: Have there been any quality scandals in the pe backed lab space? Lucas: Not major ones yet. But there's always a risk when you centralize and automate. In human lab testing, we've seen cases where a single lab's error affected thousands of patients. Veterinary medicine is less regulated, but the stakes are still high for pet owners. Luna: Speaking of regulation, what about the FDA's oversight of veterinary diagnostics? Is that a factor? Lucas: The FDA regulates test kits and analyzers, but lab-developed tests — which are common in veterinary reference labs — have historically had less oversight. That could change. The VALID Act, which has been discussed in Congress, would create a new framework for lab tests. If it passes, compliance costs could rise, which might actually accelerate consolidation because smaller labs can't afford the regulatory burden. Luna: So regulation could be a tailwind for PE, not a headwind. Lucas: Ironically, yes. The same thing happened in human lab testing after the Clinical Laboratory Improvement Amendments in the late 80s — it drove consolidation. So PE is betting that history repeats itself. Luna: What about the exit? Who buys these platforms? Another PE firm? A strategic like IDEXX or Mars? Lucas: Most likely a larger PE firm or a pension fund looking for stable, asset-light cash flows. IDEXX might be interested in certain assets, but they'd face antitrust hurdles. Mars already has Antech, so they'd be limited. The most probable exit is a sale to a larger infrastructure-style fund that wants predictable, growing revenue from a consolidated platform. Luna: So the play is: buy regional labs, roll them up, invest in tech, improve margins, then sell to a bigger fund. Lucas: That's the template. And it's happening in other areas of veterinary services too — we've seen it in imaging, in specialty referral centers. But diagnostics is particularly attractive because it's recurring: every sick pet generates a test, and wellness visits also generate panels. Luna: It reminds me of the 'razor and blades' model. The vet practice is the razor, and the lab tests are the blades. Lucas: Exactly right. And the blades are getting sharper. If these conversations have moved your work forward in some small way, listener support is what keeps this show ad-free and independent. You can find us at buy me a coffee dot com slash fexingo. Just a simple way to say the content matters. Luna: We really appreciate those who do. Now back to the lab play — one thing I'm watching is whether PE starts buying into point of care testing, the machines that sit inside a vet clinic. Lucas: That's a different model. point of care is more capital intensive — you're placing analyzers in clinics and selling reagents. IDEXX dominates that with their Catalyst and SNAP products. But some PE firms are looking at leasing arrangements or revenue-sharing models. It's a harder market to crack because of IDEXX's installed base. Luna: So for now, the action is in reference labs. But as margins compress, maybe we'll see more creative structures. Lucas: I think so. And we'll keep tracking it. That's all for this episode of The Buyout Show. Until next time.